Stephen V. Liu, MD, of the Georgetown University School of Medicine and Georgetown’s Lombardi Comprehensive Cancer Center in Washington, DC, joined Lung Cancers Today to discuss key ongoing debates and questions related to non–small cell lung cancer (NSCLC). “When we think of the ongoing debates in lung cancer, I think we can notice a theme,” Dr. Liu explained. “The theme is, are we delivering the right treatments to every patient?” ...
Expert Interviews
Watch video interviews with thoracic oncology experts to learn about the latest developments in lung cancer treatment and research.
Advertisement
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
Mara B. Antonoff, MD, FACS, discusses what could be on the horizon for surgery in stage IV lung cancer.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.
Clinical Considerations Surrounding Sublobar Resection in NSCLC: Dr. Merritt Discusses Recent Review
Robert E. Merritt, MD, MBA, FACS, shares insights on his systematic review of sublobar resection and lobectomy. 
Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.
Dr. Liu discusses remaining questions, key considerations, and how the data might shape the field moving forward.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
The trial is investigating nogapendekin alfa inbakicept-pmln in combination with immune checkpoint inhibitor therapy.
Shirish M. Gadgeel, MD, discusses the phase 1/2 ARROS-1 and ALKOVE-1 studies presented at the ESMO 2024 Congress.
Deborah Brown shares key findings from the recently released seventh annual "State of Lung Cancer" report.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
Deborah Brown shares how the American Lung Association and its LUNG FORCE initiative are raising awareness this month.
Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope.
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Lung Cancer Awareness Month is observed every November and represents a key time to take action and raise awareness.
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The three-year survival rate in the 2020 cohort of patients with NSCLC was more than double that of the 2000 cohort.
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
The 5-year scoping review provided insights on the different abstracts and educational content presented at 12 meetings.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Gene Ho, MPH, discusses real-world data on adverse events and survival outcomes with immunotherapy for NSCLC.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.